#2682 In a randomised trial of 320 RA patients, the recombinant zoster vaccine (RZV) was safe and did not trigger disease flares. But methotrexate use and older age significantly blunted antibody responses ➡️key factors to consider for vaccine strategies in RA. @RheumNow #ACR25

Inflammation skews lipid levels in RA: the “lipid paradox” Using data from CERTAIN and VARA, inflammation (hsCRP)-adjusted TC & LDL better predicted ASCVD events than standard lipids. Are we missing RA pts who need statins? @RheumNow #ACR25 A#2681

#2681 Tackling the “lipid paradox” in RA: inflammation-adjusted TC & LDL (using hsCRP correction) improved ASCVD risk prediction and flagged more high-risk patients than standard lipids. A smarter way to guide statin use in RA. @RheumNow #ACR25

In the epidemiology session on the final day of #ACR25, a large cohort study (>430k pts) showed that GLP-1 receptor agonists were linked to lower incidence of RA, gout & OA vs DPP-4 inhibitors. Adds to the growing case for GLP-1 benefits beyond glucose control. @RheumNow #2657

#ACR25 Clinical Preview by Prof Coates to be applied tomorrow! Early Tx Abstr#1677 First-line TNFi for 12-mth vs step-up = better outcomes at 5-Yr Abstr#2662 Target emulation trial = No differences in hospitalization, death/transplant RTX vs TNFi, ABA, JAK, IL-6i @RheumNow https://t.co/yostJyc5T9

• https://x.com/Yuz6Yusof/status/1983557041424908523/photo/1
• https://x.com/Yuz6Yusof/status/1983557041424908523/photo/1

Click on the link to see my take on implantable vagal nerve stimulation RCT in RA 🎥👇🏼 https://t.co/CZrFKouSqp @RheumNow #ACR25 #ABSTRACT1675

• Wired for Success: Vagal Nerve Therapy in RA | RheumNow

Nice to see a Dietary intervention study in the "Top Abstracts That Will Change My Practice in the Near Future" by L. Coates for Year in Preview Small RCT but fibres significantly improve response to treatment in the MTX treated RA group with a mean reduction of DAS28 of https://t.co/vMeIAK1P5u

• https://x.com/AurelieRheumo/status/1983553385505726631/photo/1

Fukui et al. CorEvitas study. 12076 RA patients. Propensity score matching. Kidney dysfunction (eGFR<60) reduced chance of CDAI remission (HR 0.71) or remission/LDA (HR 0.88) @RheumNow #ACR25 Abstr#2640 https://t.co/uvTjOQlGD7

• https://x.com/RichardPAConway/status/1983549389504135603/photo/1

Autologous CAR-Treg in RA, without any lymphodepletion preRx Early data from ph1, single dose Good initial response, stopped RA Rx, but some rebound Clearly work ongoing but excitement re: - CAR-Treg - RA as target dx - no lymphodepletion @minnakohlermd #ACR25 LB23 @RheumNow https://t.co/azmlFNU02R

• https://x.com/drdavidliew/status/1983540424632615108/photo/1
• https://x.com/drdavidliew/status/1983540424632615108/photo/1
• https://x.com/drdavidliew/status/1983540424632615108/photo/1
• https://x.com/drdavidliew/status/1983540424632615108/photo/1

REGULATE RA SBT-77-701 Engineered Treg cell in Refractory RA population 6patients Safety and tolerability: No DLT, CRS or ICANS Efficacy Reduction >50% in TJC and SJC 67% reduction of DAS-CRP >=2 stained up to wk 24 Impressive in pts for whom it works, yet a couple seem to https://t.co/lQAQABPhg0

• https://x.com/AurelieRheumo/status/1983539634459074639/photo/1
• https://x.com/AurelieRheumo/status/1983539634459074639/photo/1
• https://x.com/AurelieRheumo/status/1983539634459074639/photo/1

Kohler et al. Phase 1 study autologous CAR-Tregs in refractory RA. No lymphodepletion needed! 6 participants. 2 doses, second cohort with higher dose better and more sustained response. No CRS or other toxicities. @RheumNow #ACR25 Abstr#LB023 https://t.co/nWva2R7WOQ

• https://x.com/RichardPAConway/status/1983538058684403805/photo/1

#ACR25 Abstr#LB23 Phase 1 trial in 5 refractory #RA of SBT777101, a novel autologous CAR-Treg (without the need for lymphodepletion) showed promising efficacy and safety signal. No DLT, CRS or ICANS. Looking forward to larger data and in other RMDs @RheumNow https://t.co/YyGMSHjA3z

• https://x.com/Yuz6Yusof/status/1983537965545685387/photo/1
• https://x.com/Yuz6Yusof/status/1983537965545685387/photo/1

Effectiveness of b/tsDMARDs RA pts kidney dysfunction CorEvitas RA registry 9,569 pts Pts low eGFR = older more comorbidities less NSAIDs Reduced eGFR = 30% less likely to achieve remission Persists indeed of GC intake Is it a PK/PD related issue or somehow the reflection of https://t.co/KZuvPVa6eg

• https://x.com/AurelieRheumo/status/1983535872038363477/photo/1

Cellular Biomarkers of Rheumatoid Arthritis https://t.co/mLYZRX9ypm Biomarkers of RA by @jeffsparks Lots of promising biomarkers, we need validation and hopefully translation to clinical practice. @RheumNow #ACR25

• Cellular Biomarkers of Rheumatoid Arthritis